AI-Based Multi-Omics Approaches in Gynecological Cancers: A Review of Diagnostic, Prognostic, and Therapeutic Applications

Background: Gynecological cancers, particularly ovarian, endometrial, and cervical cancers, have a high disease burden in terms of incidence and mortality, and their diagnosis and treatment remain challenging. AI-based multi-omics approaches integrate multilayer data, enabling comprehensive modeling and clinical decision-making. This narrative review aimed to critically examine the current and prospective applications of these approaches in three common gynecological cancers and to evaluate their clinical potential. Methods: In this narrative review, following searches of PubMed, Web of Science, Scopus, and Google Scholar and screening of 1254 records, 51 original studies were included and synthesized qualitatively and descriptively. Relevant systematic reviews and meta-analyses were consulted only for contextualization and were not included in the primary evidence synthesis. Results: AI-based multi-omics approaches in gynecological cancers may help distinguish cancer from healthy tissue, benign from malignant conditions, and early from advanced stages; identify molecular subgroups; predict survival and recurrence; predict responses to chemotherapy and immunotherapy; and discover therapeutic targets. Minimally invasive biofluids and machine learning models showed better performance than CA125 and HE4 in some studies. Factors such as the tumor microenvironment, immunity, LDHA, and ITGA1 were associated with drug resistance in computational or preclinical studies, whereas HRD and TP53 alterations are clinically validated determinants of platinum response. In cervical cancer, the evidence was more limited and heterogeneous. Overall, the findings are promising but preliminary, and further extensive clinical validation is needed. Conclusions: AI-based multi-omics approaches may contribute to early diagnosis, molecular classification, prognostic assessment, and treatment selection in gynecological cancers; however, they remain at the proof-of-concept and initial validation stages. Prospective, multicenter, standardized studies with external validation are necessary for clinical application. These tools may serve as complementary approaches to current diagnostic pathways.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-13
DOI
https://doi.org/10.3390/jcm15228907
Primary Topic
AI in cancer detection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

AI-Based Multi-Omics Approaches in Gynecological Cancers: A Review of Diagnostic, Prognostic, and Therapeutic Applications

Mai Abdel Haleem Abusalah, Zahra Shahabinia, Do‐Youn Lee, Leila Allahqoli et al.
2 links
Journal of Clinical Medicine
AI in cancer detection
article

AI-Based Multi-Omics Approaches in Gynecological Cancers: A Review of Diagnostic, Prognostic, and Therapeutic Applications

Mai Abdel Haleem Abusalah, Zahra Shahabinia, Do‐Youn Lee, Leila Allahqoli, Afrooz Mazidimoradi, Hamid Salehiniya, Maedeh Mirasheh
article en

Abstract

Background: Gynecological cancers, particularly ovarian, endometrial, and cervical cancers, have a high disease burden in terms of incidence and mortality, and their diagnosis and treatment remain challenging. AI-based multi-omics approaches integrate multilayer data, enabling comprehensive modeling and clinical decision-making. This narrative review aimed to critically examine the current and prospective applications of these approaches in three common gynecological cancers and to evaluate their clinical potential. Methods: In this narrative review, following searches of PubMed, Web of Science, Scopus, and Google Scholar and screening of 1254 records, 51 original studies were included and synthesized qualitatively and descriptively. Relevant systematic reviews and meta-analyses were consulted only for contextualization and were not included in the primary evidence synthesis. Results: AI-based multi-omics approaches in gynecological cancers may help distinguish cancer from healthy tissue, benign from malignant conditions, and early from advanced stages; identify molecular subgroups; predict survival and recurrence; predict responses to chemotherapy and immunotherapy; and discover therapeutic targets. Minimally invasive biofluids and machine learning models showed better performance than CA125 and HE4 in some studies. Factors such as the tumor microenvironment, immunity, LDHA, and ITGA1 were associated with drug resistance in computational or preclinical studies, whereas HRD and TP53 alterations are clinically validated determinants of platinum response. In cervical cancer, the evidence was more limited and heterogeneous. Overall, the findings are promising but preliminary, and further extensive clinical validation is needed. Conclusions: AI-based multi-omics approaches may contribute to early diagnosis, molecular classification, prognostic assessment, and treatment selection in gynecological cancers; however, they remain at the proof-of-concept and initial validation stages. Prospective, multicenter, standardized studies with external validation are necessary for clinical application. These tools may serve as complementary approaches to current diagnostic pathways.

Journal of Clinical MedicineVol. 15(22)
Al-Ahliyya Amman University (JO), Kookmin University (KR), Cyprus International University (CY), Shiraz University of Medical Sciences (IR), Tehran University of Medical Sciences (IR), Birjand University of Medical Sciences (IR)
Good health and well-being
AI in cancer detection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon